Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

V-022

Supelco

Vigabatrin solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C6H11NO2
Peso molecolare:
129.16
Numero CE:
200-659-6
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

certified reference material

Livello qualitativo

300

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

NC(CCC(O)=O)C=C

InChI

1S/C6H11NO2/c1-2-5(7)3-4-6(8)9/h2,5H,1,3-4,7H2,(H,8,9)
PJDFLNIOAUIZSL-UHFFFAOYSA-N

Informazioni sul gene

human ... ABAT(18)

Categorie correlate

Descrizione generale

Vigabatrin is a newer antiepileptic sold as Sabril® in the US, Canada, Mexico and the United Kingdom and as Sabrilex in Denmark. The drug is used as an adjunctive treatment of complex partial seizures in adults and for infantile spasms in pediatric patients one month to two years of age. This certified Snap-N-Spike® Solution standard is suitable for use in LC/MS or GC/MS applications including forensic analysis, clinical toxicology, urine drug testing, or pharmaceutical research.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Sabril is a registered trademark of Lundbeck LLC
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 1

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 4

1 of 4

Rufinamide ≥98% (HPLC), powder

Sigma-Aldrich

R8404

Rufinamide

Lorazepam solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

L-901

Lorazepam solution

α-Hydroxymidazolam solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-902

α-Hydroxymidazolam solution

Midazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

M-908

Midazolam solution

The potential value of a negative finding: an illustrative example.
Kenneth Silverman et al.
JAMA psychiatry, 70(6), 571-572 (2013-04-12)
O Heinzlef et al.
Revue neurologique, 168 Suppl 3, S62-S68 (2012-06-29)
The medicinal treatment of spasticity includes use of oral treatments (baclofène and tizanidine), botulinum toxin, intrathecal baclofène and local application of alcohol or phenol. However, spasticity may not be uncomfortable and may even be useful. Therefore, all spastic diseases do
M Iu Dorofeeva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(6 Pt 2), 27-31 (2012-09-18)
Tuberous sclerosis complex is a multisystem genetic disorder. Epilepsy is very common in tuberous sclerosis and occurs in 75-92% of affected individuals during their life-time. Onset usually occurs during childhood and up to one third of children with tuberous sclerosis
Lisa M Clayton et al.
Ophthalmology, 119(10), 2152-2160 (2012-08-03)
To explore the relationship of peripapillary retinal nerve fiber layer (ppRNFL) thinning in individuals exposed to the antiepileptic drug vigabatrin with respect to 2 separate variables: cumulative vigabatrin exposure and severity of vigabatrin-associated visual field loss (VAVFL). Cross-sectional observational study.
Peter Weber et al.
Epilepsy & behavior : E&B, 24(1), 138-140 (2012-04-17)
We report the case of an adolescent girl who suffered from symptomatic refractory focal epilepsy after an arteria cerebri media insult 15 years prior to this report. Five weeks after initiation of an add-on therapy with vigabatrin, she was seizure
Visualizza tutti i documenti correlati

Global Trade Item Number

SKUGTIN
V-022-1ML4061837428616

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.